Dachaigh › Aillse Sgamhain Neo-chealla-beag › Pennsylvania › Pittsburgh
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Pittsburgh, PA
Tha 48 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Pittsburgh (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- agus 11 a bharrachd
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
A’ fastadhÌre 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- agus 8 a bharrachd
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #32, Pittsburgh
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
A’ fastadhÌre 2
- AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A’ fastadhÌre 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · 11 mìle air falbh
- UPMC Hillman Cancer Center - Monroeville, Monroeville · 11 mìle air falbh
- agus 1 a bharrachd
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A’ fastadhÌre 3
- Local Institution - 0028, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A’ fastadhÌre 1
- Research Site, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A’ fastadhÌre 1
- Research Site, Pittsburgh
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
A’ fastadhÌre 2
- Bryn Mawr Hospital, Bryn Mawr · 11 mìle air falbh
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- AHN Allegheny General Hospital, Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
A’ fastadhÌre 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A’ fastadhÌre 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A’ fastadhÌre 1/2
- Allegheny Health Network, Pittsburgh
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A’ fastadhÌre 3
- Clinical Study Site, Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
A’ fastadhÌre 1
- UPMC, Pittsburgh
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A’ fastadhÌre 2/3
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
A’ fastadhÌre 1/2
- Allegheny Singer, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A’ fastadhÌre 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
A’ fastadhÌre 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
A’ fastadhÌre 1/2
- University of Pittsburgh Medical Center, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A’ fastadhÌre 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A’ fastadhÌre 1
- UPMC, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- Allegheny Health Network, Pittsburgh
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A’ fastadhÌre 3
- UPMC-Shadyside Hospital, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A’ fastadhÌre 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
A’ fastadhÌre 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A’ fastadhÌre 2
- Allegheny General Hospital, Natrona Heights · 19 mìle air falbh
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
A’ fastadhÌre 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A’ fastadhÌre 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A’ fastadhÌre 1/2
- UPMC Hillman Cancer Center, Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
A’ fastadhÌre 1
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
A’ fastadhÌre 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- agus 11 a bharrachd
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Research Site, Pittsburgh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- agus 9 a bharrachd
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
A’ fastadhÌre 3
- Allegheny, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
A’ fastadhÌre 1
- UPMC- Hillman Cancer Center, Pittsburgh
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
A’ fastadhÌre 1
- Hillman Cancer Center, Pittsburgh
Impact of Circadian Rhythm on Immunotherapy
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
A’ fastadhÌre 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
A’ fastadhÌre 1
- UPMC Hillman Cancer Center, Pittsburgh
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Pittsburgh
- Aillse (gach seòrsa)41 sgrùdaidhean
- Aillse a' bhroilleach39 sgrùdaidhean
- Aillse colorectal32 sgrùdaidhean
- Ailse metastatach31 sgrùdaidhean
- Melanoma31 sgrùdaidhean
- Cancer Ovarian30 sgrùdaidhean
- Ailse Endometrial23 sgrùdaidhean
- Aillse Prostata23 sgrùdaidhean
- Ailseachadh nan Sgamhan23 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil22 sgrùdaidhean
- Buailteach22 sgrùdaidhean
- Depression22 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.